Disease · MONDO_0006512
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm I (4-OHT Topical Gel, Placebo) vs Arm II (Placebo, Oral Tamoxifen): deaths from any cause | 0 of 47 | 0 of 53 | 100 | NCT02993159 | Trial comparisons |
| Arm I (4-OHT Topical Gel, Placebo) vs Arm II (Placebo, Oral Tamoxifen): serious adverse events | 0 of 47 | 0 of 53 | 100 | NCT02993159 | Trial comparisons |
| Arm A vs Arm B: deaths from any cause | 0 of 42 | 0 of 44 | 86 | NCT05659563 | Trial comparisons |
| Arm A vs Arm B: serious adverse events | 0 of 42 | 0 of 44 | 86 | NCT05659563 | Trial comparisons |
| Arm I (Z-endoxifen Hydrochloride) vs Arm II (Tamoxifen Citrate): deaths from any cause | 1 of 41 | 0 of 39 | 80 | NCT02311933 | Trial comparisons |
| Arm I (Z-endoxifen Hydrochloride) vs Arm II (Tamoxifen Citrate): serious adverse events | 8 of 41 | 11 of 39 | 80 | NCT02311933 | Trial comparisons |
| Crizotinib Oral Capsule [Xalkori] Monotherapy vs Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection: Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) | 6 of 6 | 27 of 27 | 33 | NCT03620643 | Trial comparisons |
| Crizotinib Oral Capsule [Xalkori] Monotherapy vs Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection: deaths from any cause | 6 of 6 | 20 of 27 | 33 | NCT03620643 | Trial comparisons |
| Crizotinib Oral Capsule [Xalkori] Monotherapy vs Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection: serious adverse events | 4 of 6 | 5 of 27 | 33 | NCT03620643 | Trial comparisons |
| 80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes vs 80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes: Number of Participants With PSA50 Response-Besylate Sub-study | 0 of 5 | 0 of 5 | 10 | NCT01587703 | Trial comparisons |
| 80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes vs 80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes: Number of Participants With Dose Reductions or Delays-Besylate Sub-study | 3 of 5 | 1 of 5 | 10 | NCT01587703 | Trial comparisons |
| 80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes vs 80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes: Number of Participants Withdrawn Due to Toxicities-Besylate Sub-study | 0 of 5 | 0 of 5 | 10 | NCT01587703 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006512/comparisons